Reperfusion in STEMI. Pharmacoinvasive therapy The Krakow experience
|
|
|
- Scot Parks
- 10 years ago
- Views:
Transcription
1 Reperfusion in STEMI Pharmacoinvasive therapy The Krakow experience Dariusz Dudek Jacek Legutko,, Jarosław Zalewski, Krzysztof śmudka Institute of Cardiology Jagiellonian University Medical College Krakow, Poland
2 Jagiellonian University Institute of Cardiology, Krakow, Poland 2 hospitals 5 cathlabs 26 Interventional Cardiologists 4000 PCIs / year 1500 PCI in STEMI / year
3 ESC guidelines (march 2005) STEMI (within 12 hours after onset of symptoms) Patient presenting in a hospital with PCI 3 12 h Patient presenting in a hospital without PCI <3 h Immediate transfer Thrombolysis Failed Successful PCI 24h available PCI 24h not available Predischarge ischaemia Primary PCI Rescue PCI Post thrombolysis PCI Ischaemiaguided PCI
4 How to Optimize Primary PCI? Improvement of myocardial reperfusion Gp IIb/IIIa proven efficacy (class IIaA) mechanical protection thrombectomy, distal and proximal protection (class IIb C). No routine use, but: Better ST resolution, MPG no MACEs improvement, no EF? Reduction of TVR during long term follow up DES
5 Acute MI < 12 hrs in the region of 3.2 mln inhibitants Ia Ib transfer < 90min (Ib) transfer < 30min (Ia) TELE EKG abciximab Cathlab Thrombectomy and PCI PCI and abciximab PCI
6 Impact of Early Abciximab Administration before Primary Percutaneous Coronary Interventions in Anterior Myocardial Infarction on Reperfusion and Left Ventricular Function (n=59 pts) BASELINE ANGIOGRAPHY 80% 60% 48% 40% 20% p= % Early Abciximab Late Abciximab STSEGMENT RESOLUTION 60min AFTER PCI 100% 80% 60% 40% 20% 84% p= ,7% 52% p= ,3% 0% TIMI 2+3 0% STR>50% STR>70% AUC 5938+/ U/l x h CKMB AUC during 48h AUC 8324+/ U/l x h p= CARDIAC MAGNETIC RESONANCE AT 1 YEAR p=0.02 LEFT VENTRICULAR ESVI END SYSTOLIC VOLUME INDEX T.Rakowski, D. Dudek et al., AJC 2005 (TCT oral presentation)
7 EUROTRANSFER Registry European Registry on Patients with STElevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab. Principal Investigator Dariusz Dudek MD, PhD Director, Cardiac Catheterization Laboratories University Hospital, Krakow, Poland
8 EUROTRANSFER Registry currently participating centres Helsinki FINLAND Linkoping SWEDEN Przemysl POLAND Krakow POLAND Zabrze POLAND Rostock GERMANY Villingen Schwenningen GER Leeds ENGLAND Santiago de Compostela SPAIN Coruna SPAIN Treviso ITALY Reggio Emilia ITALY Mantova ITALY Arezzo ITALY Ljubljana SLOVENIA Nowy Sacz POLAND Tarnow POLAND Massa ITALY Brussels BELGIUM Lund SWEDEN Bad Oeynhausen GERMANY
9 PolishItalianHungarian Randomized ThrombEctomy Trial PIHRATE Trial PI: Dariusz Dudek
10 PIHRATE Trial n=200 pts STEMI <6hr ST elevation >3 mm in one lead TIMI 0 or 1 TIMI, ctfc, MBG RANDOMIZATION TIMI 0 or 1 POBA STENTING Grup I (n=100) THROMBECTOMY TIMI, ctfc, MBG TIMI 2 or 3 DIRECT STENTING TIMI, ctfc, MBG Grup II (n=100) PREDILATATION TIMI, ctfc, MBG STENT IMPLANTATION TIMI, ctfc, MBG ST SEGMENT RESOLUTION 60 MINUTES AFTER PCI CK/CKMB LEAK: every 6 hours for 24 hours ECHO: EF, ESV, EDV, WMSI predischarge and 6 month follow up CMR in the subgroup of patients EDV, ESV, mass and ejection fraction, delayedcontrastenhancement 6 months follow up MACE: 30 day and 6 month follow up
11 Delay >60 minutes 6090 (120) minutes >90 (120) minutes ASA / 600mg clopidogrel / UFH TIME DELAY TRANSFER WITH LYTIC / GPIIbIIIa inhibitor / COMBO THERAPY TRANSFER WITHOUT LYTIC / GPIIbIIIa inhibitor / COMBO THERAPY
12 Why to transfer patients after lytic therapy, when delay to PCI > 120 min? 1. No recommendation in guidelines to transfer patients without lytic with delay >120 min 2. Conservative treatment in hospitals without cath labs provides inferior results to PCI 3. When rescue PCI is necessary patient will be in high volume center (why to keep high risk patients 6090 minutes longer in local hospitals for reperfusion assessment in ecg?) 4. Post lytic PCI within 24 hours is recommended in guidelines
13 p. miechowski 51,5 tys. p. olkuski 114,7 tys. mortality 3.5% Kraków + p. krakowski 998,8 tys. p. proszowicki 43,6 tys. p. dąbrowski 58,6 tys year p. oświęcimski 153,1 tys. p. chrzanowski 128,7 tys. p. wadowicki 153,4 tys. pierwotna PCI p. wielicki 102,5 tys. p. myślenicki 114,9 tys. p. suski p. limanowski 81,5 tys. 120,2 tys. p. nowotarski 179,9 tys. p. bocheński 99,7 tys. Tarnów + p. brzeski p. tarnowski 89,7 tys. 310,5 tys. Nowy Sącz + p. nowosądecki 279,4 tys. p. gorlicki 106,4 tys. 23 hospitals referring STEMI pts to Krakow Center ½ tpa +abciximab and transfer FACILITATED PCI p. tatrzański 65,3 tys.
14 2 years June 2001 June 2003 STEMI n=2362 (age <75 years) PRIMARY PCI vs FACILITATED PCI 30day MACE 8% 6% 4% 3,4% 3,0% NS 4,2% 3,9% 5,0% 4,8% 2% 0,8% 0,9% 0,8% 0,9% 0% Death re MI re PCI death + re MI All MAC E PRIMARY FACILITATED D. Dudek et al., AJC 2003 D. Dudek et al., AHA 2005, featured research
15 Primary PCI vs. ReducedDose Facilitated PCI Death Reinfarction Revascularization Bleeding P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone P Value Facilitated Lytic Alone Authors Titles Ross et al. PACT 3.3% 3.6% % 3% % 7.3% % 12.9% 0.84 Dudek et al. 3.5% 1.0% 1.5% 3.0% Kastrati et al. BRAVE 1.6% 1.6% NS 0% 0.8% NS 1.6% 5.6% 0.16 Maioli et al. 6.1% 6.3% % 0% % 6.2% ADVANCE MI Inv. ADVANCE MI 0% 6.8% % 1.4% % 23% 0.05 Borden and Faxon, J Am Coll Cardiol, 2006;48:1120 8
16 ST,, high risk, lytic lyticeligible, < h UFH UFH U/kg U/kg (max (max 3000); 3000); 7 U/kg/h U/kg/h Reteplase 2 x 5 U bolus bolus (30 ) (30 ) Abciximab mg/kg mg/kg bolus; bolus; µg/kg/min µg/kg/min x h (maximum 10 µg/min) (maximum 10 µg/min) IMMEDIATE PCI Immediate Transfer Transfer to to Cath CathLab for for PCI; PCI; after after PCI PCI pat. pat. remains remains in in the the hospital hospital where where PCI PCI was was performed or or is is transferred back back to to referring hospital hospital MEDICAL TREATMENT + RESCUE CCU CCU Admission; Transfer Transfer for for PCI PCI only only if if persistent ST ST elevation at at min min (>50% (>50% basal basal ECG), ECG), chest chest pain pain or or hemodynamic compromise Primary Endpoint: Death, Reinfarction,, Refractory Ischemia at at Days Days Di Mario, Bolognese, Maillard, Dudek et al Am Heart J, 2004
17 2 new centers with 24h/7days service for 0.5 mln population each p. oświęcimski 153,1 tys. p. chrzanowski 128,7 tys. p. wadowicki 153,4 tys. p. olkuski 114,7 tys. p. miechowski 51,5 tys. p. proszowicki Kraków + 43,6 tys. p. krakowski 998,8 tys ,2 tys. SMALL NETWORK for 0.5 mln inhabitatns p. bocheński 99,7 tys. p. wielicki 102,5 tys. p. brzeski 89,7 tys. app. 350 STEMI PCI/ year app. 350 NSTEMI/UA PCI/ year 45 operators p. dąbrowski 58,6 tys. Tarnów + p. tarnowski 310,5 tys. 458,8 tys year FACILITATED PCI CARESS study p. suski 81,5 tys. p. nowotarski 179,9 tys. p. myślenicki 114,9 tys. p. tatrzański 65,3 tys. p. limanowski 120,2 tys. 506 tys. Nowy Sącz + p. nowosądecki 279,4 tys. p. gorlicki 106,4 tys. SMALL NETWORK for 0.5 mln inhabitatns app. 350 STEMI PCI/ year app. 350 NSTEMI/UA PCI/ year 45 operators
18 Primary PCI Clinical usefulness of different thrombectomy devices during primary PCI needs further clinical trials DES for Primary PCI need large clinical studies with long term outcome
19 Gp IIb/IIIa inhibitors and Primary PCI 1. In STEMI patients, pharmacologic pretreatment prior to PCI improves initial TIMI3 flow 2. It is reasonable to start GPIIb/IIIa as early as possible prior to primary angioplasty 3. Early IIb/IIIa administration could be more beneficial for higher risk AMI, early presenters and when time to PCI is longer (app. 60 minutes door to balloon time)
20 Fibrynolysis & PCI 1. Facilitated PCI with full dose lytic is not recommended (early routine PCI<12 hrs and immediate after lysis) 2. Pharmaco invasive therapy is permitted and recommended by ESC guidelines (PCI within 24 hrs after lysis). 3. Pharmaco invasive therapy could be recommended for STEMI < 23 hrs onset when long delay > 120 minut expected 4. High risk pts after lytic should be tranfered to PCI centers for clinical/angio evaluation (rescue PCI; PCI 24 hrs)
PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators
Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization
Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project
Networking for optimal treatment of STEMI and NSTEMI European Stent for life Project Dariusz Dudek on behalf of Department of Interventional Cardiology, Institute of Cardiology, Krakow, Poland The European
REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO
REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary
Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
Antiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the
Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators
Duration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
Implementing a Prehospital 12-Lead Program
Implementing a Prehospital 12-Lead Program Corey M. Slovis, M.D. Professor and Chairman Department of Emergency Medicine Vanderbilt University Medical Center Medical Director, Metro Nashville Fire Department
Antiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν
ΝΠθ ζζάθδκνσθϋ λδκν έΰκ μνεδν ιωθκ κεκη δεάμνι λδεάμ έΰζβν έκ,νσϊίί κν1γν λδζέκνβί1γ Α Α φ ; έζ δκμννένσθόμ ηί δεόμνκλ δκζόΰκμ, θν δ γθ άμνγνκλ /εάμ ΚζδθδεάμΝ λωεζδθδεάμν ένivus Scientific Director, Mediolanum
DATE: 29 August 2012 CONTEXT AND POLICY ISSUES
TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management
DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example
The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example Ulf Stenestrand, MD, PhD Department of Cardiology University Hospital Linköping Chairman RIKS-HIA Register
Cilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
Stent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
ESC PCI Guidelines: / Sigmund Silber et al. 1
For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo
Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
Utilizing the Cath Lab for Cardiac Arrest
Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013
Antonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
Management of Acute Coronary Syndrome / NSTEMI
CLINICAL GUIDELINE Management of Acute Coronary Syndrome / NSTEMI For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: All clinical areas Medical and
Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC
Update in Acute Coronary Syndromes Hani Jneid, MD, FACC, FAHA Baylor College of Medicine Michael E. DeBakey VAMC NAAMA 37 th National Medical Convention September 5 th, 2015 Atherosclerosis Coronary Heart
Translating Science to Health Care: the Use of Predictive Models in Decision Making
Translating Science to Health Care: the Use of Predictive Models in Decision Making John Griffith, Ph.D., Associate Dean for Research Bouvé College of Health Sciences Northeastern University Topics Clinical
Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI
Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
Canadian Journal of Cardiology 27 (2011) 529 533. Editorial
Canadian Journal of Cardiology 27 (2011) 529 533 Editorial From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting
Trial Design. From the a Southlake Regional Health Centre, Newmarket, Ontario, Canada, b University of Toronto, Toronto, Ontario, Canada,
Trial Design Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Warren J. Cantor, MD, a,b David
California Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
The Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
Como mejorar el manejo médico de los diabéticos con SCA
DIABETES Y ENFERMEDAD CORONARIA EN 2011 Como mejorar el manejo médico de los diabéticos con SCA Antonio Fernández-Ortiz Jueves, 20 Octubre 2011 INSTITUTO CARDIOVASCULAR Conflicto de interés: Antonio Fernández-Ortiz
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
La facilitazione alla PCI con statine
La facilitazione alla PCI con statine Bertinoro, 16 aprile 2010 Aldo Miola, M.D., Ph.D. Medical Manager Primary Care Pfizer Italy 1 Are statins beneficial in patients undergoing PCI? 2 3 Statin therapy
Aktuelle Literatur aus der Notfallmedizin
05.02.2014 Aktuelle Literatur aus der Notfallmedizin prä- und innerklinisch Aktuelle Publikationen aus 2012 / 2013 PubMed hits zu emergency medicine 12,599 Abstract OBJECTIVES: Current American Heart
EMR Tutorial Acute Coronary Syndrome
EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care
Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care The Mission: Lifeline Certification Program will acknowledge STEMI Systems, EMS, Non-PCI/STEMI Referral Centers and PCI/STEMI Receiving
Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH
Emergency Management Strategies for Acute Myocardial Infarction - Code R at LGH PAUL N. CASALE, M.D., F.A.C.C. Chief, Division of Cardiology and Medical Director of Cardiology, Lancaster General Hospital
OCT STEMI: OCT guidance during stent implantation
OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
STEMI Care in WV Mission: Lifeline -AHA initiative. Christopher B. Granger, MD, FACC Mayme Lou Roettig, RN, MSN
STEMI Care in WV Mission: Lifeline -AHA initiative Christopher B. Granger, MD, FACC Mayme Lou Roettig, RN, MSN Christopher B. Granger, MD, F.A.C.C Director of Cardiac Care Unit Duke University Medical
Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics Yen Tibayan, M.D. Division of Cardiovascular Medicine Case Presentation 69 y.o. woman calls 911 with the complaint of
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne
How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne What do the guidelines say? What happens with warfarin
Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
Optimal Duration of Dual Antiplatelet Therapy
Optimal Duration of Dual Antiplatelet Therapy Luis A Guzman, MD, FACC, FSCAI Associate Professor of Medicine Director, Cardiac and Vascular Cath Lab University of Florida College of Medicine - Jacksonville
6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
Mission: Lifeline EMS Recognition Guide
Mission: Lifeline EMS Recognition Guide This Mission: Lifeline EMS Recognition Guide was developed to provide information about Mission: Lifeline EMS Recognition processes and criteria. If you have any
Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith
Māori Pathways to and Through Health Care for STEMIs in New Zealand Summer Studentship Research by Ellie Tuzzolino- Smith Terminology & Current Practice STEMI: S-T elevation Myocardial Infarction. Determined
URN: Family name: Given name(s): Address:
State of Queensland (Queensland Health) 2015 Licensed under: http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Contact: [email protected] Facility:... Clinical pathways
What s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
Is There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie
MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE Peter Wenaweser Universitätsklinik für Kardiologie Scientific Advances & Cardiovascular Mortality 1950 to 2010 Nabel EM and Braunwald
Non-invasive functional testing in 2014
Non-invasive functional testing in 2014 Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Disclosures: Research grants: Edwards and Siemens Non-invasive functional testing in 2014
ACTION Registry GWTG Version 2.4
ACTION Registry GWTG Version 2.4 Dr. Joanne Foody Kim Hustler The following relationships exist: Dr. Foody:Janssen, Sanofi, Genzyme, Aegerion, Amarin, BristolMeyersSquibb, Abbott, Gilead, ACC, Pfizer,
University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
ST Segment Elevation Nothing is ever as hard (or easy) as it looks
ST Segment Elevation Nothing is ever as hard (or easy) as it looks Cameron Guild, MD Division of Cardiology University of Mississippi Medical Center February 17, 2012 Objectives 1. Describe the electrical
Redefining the NSTEACS pathway in London
Redefining the NSTEACS pathway in London Sotiris Antoniou Consultant Pharmacist, Cardiovascular Medicine, Barts and The London NHS Trust and Project Lead, North East London Cardiovascular and Stroke Network
NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3
1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications
The Bioresorbable Vascular Stent Dr Albert Ko
The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of
How do you decide on rate versus rhythm control?
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
Mission: Lifeline North Texas STEMI Workshop. The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN
STEMI Workshop The Model STEMI Referring Center (non-pci capable) Trisha Wren, RN, BSN Faculty Disclosure Information Trisha Wren, RN, BSN The Model STEMI Referring Center (non PCI capable) FINANCIAL DISCLOSURE:
Triple thérapie anti-thrombotique chez le coronarien. Y Cottin Dijon
Triple thérapie anti-thrombotique chez le coronarien Y Cottin Dijon «Dans la vie, rien n est à craindre, tout est à comprendre» Marie Curie Epidémiologie Aspirine/Clopidogrel/Ticagrelor/Prasugrel Durée?
Gregg W. Stone, MD. Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation
INFUSE-AMI A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI Gregg W. Stone,
Main Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes
Resuscitation (2005) 67S1, S87 S96 European Resuscitation Council Guidelines for Resuscitation 2005 Section 5. Initial management of acute coronary syndromes Hans-Richard Arntz, Leo Bossaert, Gerasimos
Description of problem Description of proposed amendment Justification for amendment ERG response
KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without
HAAD JAWDA Quality KPI; waiting times. December 2015
HAAD JAWDA Quality KPI; waiting times December 2015 Page 1 of 13 Type: Waiting Time Indicator Indicator Number: WT001 Primary Care Appointment- Outpatient Setting Time to see a HAAD licensed family physician
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.
The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,
Acute Coronary Syndromes Education for Healthcare Providers. Hani Kozman, MD Cardiology Division SUNY Upstate Medical University
Acute Coronary Syndromes Education for Healthcare Providers Hani Kozman, MD Cardiology Division SUNY Upstate Medical University NSTEMI 2 Types ACS: Chest pain related to a progressively enlarging intracoronary
MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
